Market Research Logo

Breast Cancer - Pipeline Review, H1 2015

Breast Cancer - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Breast Cancer - Pipeline Review, H1 2015’, provides an overview of the Breast Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Breast Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Breast Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Breast Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Breast Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Breast Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Breast Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Breast Cancer Overview
Therapeutics Development
Breast Cancer - Therapeutics under Development by Companies
Breast Cancer - Therapeutics under Investigation by Universities/Institutes
Breast Cancer - Pipeline Products Glance
Breast Cancer - Products under Development by Companies
Breast Cancer - Products under Investigation by Universities/Institutes
Breast Cancer - Companies Involved in Therapeutics Development
Breast Cancer - Therapeutics Assessment
Drug Profiles
Breast Cancer - Recent Pipeline Updates
Breast Cancer - Dormant Projects
Breast Cancer - Discontinued Products
Breast Cancer - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Breast Cancer, H1 2015
Number of Products under Development for Breast Cancer - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Development by Companies, H1 2015 (Contd..3)
Number of Products under Development by Companies, H1 2015 (Contd..4)
Number of Products under Development by Companies, H1 2015 (Contd..5)
Number of Products under Development by Companies, H1 2015 (Contd..6)
Number of Products under Development by Companies, H1 2015 (Contd..7)
Number of Products under Development by Companies, H1 2015 (Contd..8)
Number of Products under Development by Companies, H1 2015 (Contd..9)
Number of Products under Development by Companies, H1 2015 (Contd..10)
Number of Products under Development by Companies, H1 2015 (Contd..11)
Number of Products under Development by Companies, H1 2015 (Contd..12)
Number of Products under Development by Companies, H1 2015 (Contd..13)
Number of Products under Development by Companies, H1 2015 (Contd..14)
Number of Products under Development by Companies, H1 2015 (Contd..15)
Number of Products under Development by Companies, H1 2015 (Contd..16)
Number of Products under Development by Companies, H1 2015 (Contd..17)
Number of Products under Development by Companies, H1 2015 (Contd..18)
Number of Products under Development by Companies, H1 2015 (Contd..19)
Number of Products under Development by Companies, H1 2015 (Contd..20)
Number of Products under Development by Companies, H1 2015 (Contd..21)
Number of Products under Development by Companies, H1 2015 (Contd..22)
Number of Products under Development by Companies, H1 2015 (Contd..23)
Number of Products under Development by Companies, H1 2015 (Contd..24)
Number of Products under Development by Companies, H1 2015 (Contd..25)
Number of Products under Development by Companies, H1 2015 (Contd..26)
Number of Products under Development by Companies, H1 2015 (Contd..27)
Number of Products under Development by Companies, H1 2015 (Contd..28)
Number of Products under Development by Companies, H1 2015 (Contd..29)
Number of Products under Investigation by Universities/Institutes, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..5)
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..6)
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..7)
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Development by Companies, H1 2015 (Contd..3)
Products under Development by Companies, H1 2015 (Contd..4)
Products under Development by Companies, H1 2015 (Contd..5)
Products under Development by Companies, H1 2015 (Contd..6)
Products under Development by Companies, H1 2015 (Contd..7)
Products under Development by Companies, H1 2015 (Contd..8)
Products under Development by Companies, H1 2015 (Contd..9)
Products under Development by Companies, H1 2015 (Contd..10)
Products under Development by Companies, H1 2015 (Contd..11)
Products under Development by Companies, H1 2015 (Contd..12)
Products under Development by Companies, H1 2015 (Contd..13)
Products under Development by Companies, H1 2015 (Contd..14)
Products under Development by Companies, H1 2015 (Contd..15)
Products under Development by Companies, H1 2015 (Contd..16)
Products under Development by Companies, H1 2015 (Contd..17)
Products under Development by Companies, H1 2015 (Contd..18)
Products under Development by Companies, H1 2015 (Contd..19)
Products under Development by Companies, H1 2015 (Contd..20)
Products under Development by Companies, H1 2015 (Contd..21)
Products under Development by Companies, H1 2015 (Contd..22)
Products under Development by Companies, H1 2015 (Contd..23)
Products under Development by Companies, H1 2015 (Contd..24)
Products under Development by Companies, H1 2015 (Contd..25)
Products under Development by Companies, H1 2015 (Contd..26)
Products under Development by Companies, H1 2015 (Contd..27)
Products under Development by Companies, H1 2015 (Contd..28)
Products under Development by Companies, H1 2015 (Contd..29)
Products under Development by Companies, H1 2015 (Contd..30)
Products under Development by Companies, H1 2015 (Contd..31)
Products under Development by Companies, H1 2015 (Contd..32)
Products under Development by Companies, H1 2015 (Contd..33)
Products under Development by Companies, H1 2015 (Contd..34)
Products under Development by Companies, H1 2015 (Contd..35)
Products under Development by Companies, H1 2015 (Contd..36)
Products under Development by Companies, H1 2015 (Contd..37)
Products under Development by Companies, H1 2015 (Contd..38)
Products under Development by Companies, H1 2015 (Contd..39)
Products under Development by Companies, H1 2015 (Contd..40)
Products under Development by Companies, H1 2015 (Contd..41)
Products under Development by Companies, H1 2015 (Contd..42)
Products under Development by Companies, H1 2015 (Contd..43)
Products under Development by Companies, H1 2015 (Contd..44)
Products under Development by Companies, H1 2015 (Contd..45)
Products under Development by Companies, H1 2015 (Contd..46)
Products under Investigation by Universities/Institutes, H1 2015
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2015 (Contd..3)
Products under Investigation by Universities/Institutes, H1 2015 (Contd..4)
Products under Investigation by Universities/Institutes, H1 2015 (Contd..5)
Products under Investigation by Universities/Institutes, H1 2015 (Contd..6)
Products under Investigation by Universities/Institutes, H1 2015 (Contd..7)
Products under Investigation by Universities/Institutes, H1 2015 (Contd..8)
Products under Investigation by Universities/Institutes, H1 2015 (Contd..9)
Products under Investigation by Universities/Institutes, H1 2015 (Contd..10)
Breast Cancer - Pipeline by 3-V Biosciences, Inc., H1 2015
Breast Cancer - Pipeline by A&G Pharmaceutical, Inc., H1 2015
Breast Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2015
Breast Cancer - Pipeline by AB Science, H1 2015
Breast Cancer - Pipeline by AbbVie Inc., H1 2015
Breast Cancer - Pipeline by AbGenomics International, Inc., H1 2015
Breast Cancer - Pipeline by Actinium Pharmaceuticals, Inc., H1 2015
Breast Cancer - Pipeline by Adaptimmune Limited, H1 2015
Breast Cancer - Pipeline by Advanced Cancer Therapeutics, H1 2015
Breast Cancer - Pipeline by Advanced Proteome Therapeutics Corporation, H1 2015
Breast Cancer - Pipeline by Advaxis, Inc., H1 2015
Breast Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2015
Breast Cancer - Pipeline by Aegis Therapeutics, LLC, H1 2015
Breast Cancer - Pipeline by Aerpio Therapeutics, Inc., H1 2015
Breast Cancer - Pipeline by Aeterna Zentaris Inc., H1 2015
Breast Cancer - Pipeline by Affichem, H1 2015
Breast Cancer - Pipeline by Aileron Therapeutics, Inc., H1 2015
Breast Cancer - Pipeline by Alchemia Limited, H1 2015
Breast Cancer - Pipeline by Alethia Biotherapeutics Inc., H1 2015
Breast Cancer - Pipeline by Almac Discovery Ltd., H1 2015
Breast Cancer - Pipeline by AlphaMab Co., Ltd, H1 2015
Breast Cancer - Pipeline by AlphaVax, Inc., H1 2015
Breast Cancer - Pipeline by Amarna Therapeutics B.V., H1 2015
Breast Cancer - Pipeline by Ambrx, Inc., H1 2015
Breast Cancer - Pipeline by Amgen Inc., H1 2015
Breast Cancer - Pipeline by Ampio Pharmaceuticals, Inc., H1 2015
List of Figures
Number of Products under Development for Breast Cancer, H1 2015
Number of Products under Development for Breast Cancer - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report